ACAD
Acadia Pharmaceuticals Inc

13,090
Mkt Cap
$4.16B
Volume
2,766.00
52W High
$28.35
52W Low
$13.40
PE Ratio
15.82
ACAD Fundamentals
Price
$24.59
Prev Close
$24.73
Open
$25.04
50D MA
$25.77
Beta
0.94
Avg. Volume
1.26M
EPS (Annual)
$1.36
P/B
4.53
Rev/Employee
$1.46M
$2,348.74
Loading...
Loading...
News
all
press releases
Wolfe Research Upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) to "Strong-Buy"
Wolfe Research upgraded shares of ACADIA Pharmaceuticals to a "strong-buy" rating in a report on Monday...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Citigroup Inc. Sells 92,770 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Citigroup Inc. lessened its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 5.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned...
MarketBeat·5h ago
News Placeholder
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March...
Business Wire·2d ago
News Placeholder
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Up - Should You Buy?
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Up - What's Next...
MarketBeat·2d ago
News Placeholder
Jupiter Asset Management Ltd. Cuts Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Jupiter Asset Management Ltd. lessened its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 25.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm...
MarketBeat·4d ago
News Placeholder
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
News Placeholder
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago
News Placeholder
Ovintiv to Report Q4 Earnings: What's in Store for the Stock?
OVV is expected to report lower revenues than in the year-ago period. However, the company is also expected to have faced reduced costs and expenses.
Zacks·7d ago
News Placeholder
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by GSA Capital Partners LLP
GSA Capital Partners LLP raised its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 210.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·7d ago
News Placeholder
ACADIA Pharmaceuticals (ACAD) to Release Quarterly Earnings on Wednesday
ACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing its Q4 2025 earnings after the market closes on Wednesday, February 25. (View Earnings Report at...
MarketBeat·7d ago
<
1
2
...
>

Latest ACAD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.